DOCSLIB.ORG

Migraleve Pink

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Migraleve Pink GB_Migraleve Complete 12s /24s & Pink 12s / 24s & Yellow 24s_PIL 13.05.2021 English 402318125_r1 N/A Brochure/Leaflet/Insert 145 X 250 MM 360146G DC-Pharmalog_Val De Reuil_Upper Normandy_France CHILD 360146F Westrock Saint Pierre des Corps 6 mm 963 Offset Printing 6 mm 6 mm 8521107 / 5209117 / 8525207 / 5209719 / 5210316 N/A EMEA_2021_00043038_000 PC-0002781 12 mm right margin n If you have taken any other painkillers in the last four hours. ® n If you are allergic to paracetamol, codeine or buclizine or any of the other Warnings and precautions ingredients of this medicine (listed in section 6). Codeine is transformed to morphine in the liver by an enzyme. Morphine is the n If you are taking other medicines containing paracetamol. substance that produces pain relief. Some people have a variation of this enzyme Paracetamol, Codeine phosphate & Buclizine hydrochloride n In children under 12 years of age. and this can affect people in different ways. In some people, morphine is not BLACK RHODAMINE n In children and adolescents (0-18 years of age) after removal of their tonsils or n For the short term treatment of acute moderate pain which is not relieved by produced or produced in very small quantities, and it will not provide enough RED adenoids for obstructive sleep apnoea syndrome. pain relief. Other people are more likely to get serious side effects because a paracetamol, ibuprofen or aspirin alone such as migraine attacks, including the n If you have recently developed shallow breathing. LITHO OFFSET LITHO OFFSET symptoms of migraine headache, nausea and vomiting. very high amount of morphine is produced. If you notice any of the following n If your bowel is obstructed or does not work properly. side effects, you must stop taking this medicine and seek immediate medical REPRESENTATION: Colours represented with a diagonal line have been modified to aid PDF approval. n You should only take this product for a maximum of three days at a time. If you need to n If you have a head injury or raised pressure in your skull (may cause painful eyes, take it for longer than three days you should see your doctor or pharmacist for advice. advice: slow or shallow breathing, confusion, sleepiness, small pupils, feeling or change in vision or headache behind the eyes). being sick, constipation, lack of appetite. n This medicine contains codeine which can cause addiction if you take it continuously n If you know that you metabolise codeine into morphine very rapidly. for more than three days. This can give you withdrawal symptoms from the medicine n If you are breastfeeding. Children and adolescents when you stop taking it. If any of these apply to you, get advice from a doctor or pharmacist without Use in children and adolescents after surgery n If you take this medicine for headaches for more than three days it can make them worse. using MIGRALEVE®. Codeine should not be used in children and adolescents after removal of their n This medicine is for use by adults and children aged 12 years and over. tonsils or adenoids for Obstructive Sleep Apnoea Syndrome. Now read this whole leaflet carefully before you use this medicine. Talk to your doctor or pharmacist... Use in children with breathing problems Keep the leaflet: you might need it again. n If you suffer from liver or kidney disease. Codeine is not recommended in children with breathing problems, since the n If you suffer from alcoholic liver disease or alcoholic dependence. symptoms of morphine toxicity may be worse in these children. 1 What the medicine is for n If you are taking any other medicines. n If you have closed angle glaucoma (increased pressure in the eye). If you are pregnant or breastfeeding For the short term treatment of acute moderate pain which is not relieved by n If you have difficulty passing water or unable to pass water. Ask your doctor or pharmacist for advice before taking this medicine if you are paracetamol, ibuprofen or aspirin alone such as migraine attacks, including the n If you have prostate disease. pregnant. symptoms of migraine headache, nausea and vomiting. n If you suffer from fits. FuturaBT-MediumItalic HelveticaNeueLTStd-Cn Smallest Text Size ® Do not take codeine while you are breastfeeding. Codeine and morphine passes There are two types of MIGRALEVE tablet available: n If you suffer from asthma or breathing problems or other lung disease. into breast milk. HelveticaNeueLTPro-Bd Wingdings-Regular 6.25pt n MIGRALEVE® Pink tablets n If you are taking any other medicines including: n ® tablets Special warnings about drowsiness HelveticaNeueLTPro-BdCn Ave. Text Size MIGRALEVE Yellow n metoclopramide or domperidone (used to treat nausea and vomiting) They are available separately or together in one pack. n cholestyramine (used to treat high cholesterol) Driving and using machines HelveticaNeueLTPro-Cn ® 6.5pt MIGRALEVE Pink tablets contain paracetamol and codeine which eases pain and buclizine which n if you are taking or have taken in the last two weeks, Monoamine Oxidase Inhibitors The medicine can affect your ability to drive as it may make you sleepy or dizzy. HelveticaNeueLTPro-CnO helps relieve nausea and vomiting. The Pink tablets therefore treat all the symptoms of migraine. If (MAOIs such as moclobemide, phenelzine, tranylcypromine or selegiline) for n Do not drive while taking this medicine until you know how it affects you. ® HelveticaNeueLTPro-HvCn Largest Text Size taken at the first sign of a migraine, MIGRALEVE Pink tablets can prevent an attack from developing. depression or other conditions. n It is an offence to drive if this medicine affects your ability to drive. MIGRALEVE® Yellow tablets contain paracetamol and codeine for the treatment of pain and relief n anticoagulants (drugs that thin the blood, such as warfarin) However, you would not be committing an offence if: Fonts used Fonts 12.5pt HelveticaNeueLTPro-Roman of continuing migraine symptoms. They should always be taken after the first dose of n anticonvulsants such as carbamazepine, phenytoin, fosphenytoin, phenobarbital or n The medicine has been prescribed to treat a medical or dental problem and 2021-04-13 08:53:37 MIGRALEVE® Pink tablets. primidone (used to treat epilepsy) n You have taken it according to the instructions given by the prescriber or in Codeine can be used in children over 12 years of age for the short-term relief of moderate n antimuscarinic drugs e.g. atropine (drug given prior to surgery and for some eye the information provided with the medicine and pain that is not relieved by other painkillers such as paracetamol or ibuprofen alone. and bowel conditions) n It was not affecting your ability to drive safely This product contains codeine. Codeine belongs to a group of medicines called opioid analgesics n Drugs affecting the brain: Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive which act to relieve pain. It also contains paracetamol, another analgesic to relieve pain. - drugs used to decrease anxiety or to help you sleep (e.g. benzodiazepines or while taking this medicine. barbiturates) - antidepressants (e.g. tricyclic antidepressants) 3 How to take this medicine 2 Before taking this medicine - drugs used for mental conditions causing delusions or hallucinations n This medicine contains paracetamol. Do not take anything else containing paracetamol (e.g. phenothiazines) Check the tables below to see how much medicine to take. while taking this medicine. n General anaesthetics n For oral use only. Swallow the tablets with a glass of water. n Do not take for longer than three days at a time. n Muscle relaxants n Taking codeine regularly for a long time can lead to addiction, which might cause you to n Do not take less than four hours after taking other painkillers. n Other painkillers containing paracetamol or codeine or products similar to codeine n Always start with MIGRALEVE® Pink tablets. feel restless and irritable when you stop the tablets. e.g. tramadol, morphine n Taking a painkiller for headaches too often or for too long can make them worse. n Do not take more than the stated dose shown below. If you are not sure about the medicine you are taking, show the bottle or pack to n This medicine should not be taken for more than 3 days. If the pain does not This medicine is suitable for most people but a few people should not use it. your pharmacist. improve after 3 days, talk to your doctor for advice. If you are in any doubt, talk to your doctor or pharmacist. If any of these bullet points apply to you now or in the past, talk to a Children under 12 years Do not use this medicine... doctor or pharmacist. Do not give to children below the age of 12 years, n Unless your migraines have been diagnosed by a doctor. due to the risk of severe breathing problems. turn over t margin 14 mm f le spot = 12 x 2 centered in the margin of 14 mm Distance between cutted line/middel of the spot = 51.6 mm GB_Migraleve Complete 12s /24s & Pink 12s / 24s & Yellow 24s_PIL 13.05.2021 English 402318125_r1 N/A Brochure/Leaflet/Insert 145 X 250 MM Barcodes placed at 14 mm Hight for bars : 10 mm 360146G DC-Pharmalog_Val De Reuil_Upper Normandy_France code Laetus 963 CHILD 360146F Westrock Saint Pierre des Corps 14 963 Offset Printing 8521107 / 5209117 / 8525207 / 5209719 / 5210316 N/A le f 12 mm t margin EMEA_2021_00043038_000 PC-0002781 Children 12 – 15 years Other effects which may occur include: Very common: 5 Storing this medicine Age Dose n Feeling sick, sleepiness (although desire to sleep can be a symptom of migraine).
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0100249 A1 Sears Et Al
    US 201401.00249A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0100249 A1 Sears et al. (43) Pub. Date: Apr. 10, 2014 (54) THERAPEUTIC TREATMENT A63/37 (2006.01) A613 L/45 (2006.01) (71) Applicants: Douglas Sears, Oak Park, CA (US); A613 L/4458 (2006.01) Michael Reilly, Oak Park, CA (US) (52) U.S. Cl. CPC ............... A61K 45/06 (2013.01); A61 K3I/451 (72) Inventors: Douglas Sears, Oak Park, CA (US); (2013.01): A613 L/4458 (2013.01); A61 K Michael Reilly, Oak Park, CA (US) 3 1/137 (2013.01); A61 K31/165 (2013.01) USPC .......................................................... S14/325 (21) Appl. No.: 14/046,528 (57) ABSTRACT (22) Filed: Oct. 4, 2013 This invention discloses a treatment for a patient receiving O O medication to treat an attention deficit disorder Such as Related U.S. Application Data ADHD wherein the treatment results in a loss of appetite and (60) Provisional application No. 61/744,948, filed on Oct. impairment of the patient's attentiveness. The treatment com 9, 2012, now abandoned. bines a treatment for an attention deficit disorder with an appetite stimulant, wherein the appetite stimulant increases Publication Classification the caloric intake of a patient, which can increase the patients attentiveness. The combination treatment can be given for an (51) Int. Cl. indefinite, including, without limitation, life-long, to allow a A6 IK 45/06 (2006.01) patient to maintain normal caloric intake during treatment for A6 IK3I/65 (2006.01) an attention deficit disorder. 8aasaias: Patent Application Publication Apr. 10, 2014 Sheet 1 of 22 US 2014/010O249 A1 Figure i: improvement in Atiention with increased Caiotic intake 8aakast Patent Application Publication Apr.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • PRODUCT INFORMATION Buclizine (Hydrochloride) Item No
    PRODUCT INFORMATION Buclizine (hydrochloride) Item No. 25641 CAS Registry No.: 129-74-8 Formal Name: 1-[(4-chlorophenyl)phenylmethyl]-4-[[4-(1,1- dimethylethyl)phenyl]methyl]-piperazine, dihydrochloride Synonym: NSC 25141 MF: C H ClN • 2HCl 28 33 2 N FW: 506.0 Purity: ≥98% N Cl UV/Vis.: λmax: 224, 279 nm Supplied as: A crystalline solid • 2HCl Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Buclizine (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the buclizine (hydrochloride) in the solvent of choice. Buclizine (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of buclizine (hydrochloride) in these solvents is approximately 0.11, 0.17, and 5 mg/ml, respectively. Description Buclizine is an antihistamine.1 It reduces bronchoconstriction and lethality induced by aerosolized histamine in guinea pigs when administered at a dose of 1 mg/kg. Buclizine (40-200 mg/kg) induces gross malformations, including fusion of the tongue to the palate, cleft palate, micrognathia, and micromelia, and bone malformations in rats.2 It also inhibits cancer cell growth by binding to translationally controlled tumor protein (TCTP) and inducing cell differentiation.3 Formulations containing buclizine have been used to treat nausea induced by pregnancy and motion sickness. References 1. Schiller, I.W. and Lowell, F.C. Toxicologic and clinical appraisal of buclizine, a new antihistaminic compound. J. Allergy 27(1), 63-67 (1956).
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Headache Management: Pharmacological Approaches
    REVIEW Headache management: Pract Neurol: first published as 10.1136/practneurol-2015-001167 on 3 July 2015. Downloaded from pharmacological approaches Alex J Sinclair,1,2 Aaron Sturrock,2 Brendan Davies,3 Manjit Matharu4 ▸ Additional material is ABSTRACT be very rewarding for the clinician. The published online only. To view Headache is one of the most common conditions purpose of this article, the first of two please visit the journal online (http://dx.doi.org/10.1136/ presenting to the neurology clinic, yet a linked articles, is to provide an up-to-date practneurol-2015-001167). significant proportion of these patients are overview of the pharmacological manage- unsatisfied by their clinic experience. Headache ment of common headache disorders 1Department of Neurobiology, School of Clinical and can be extremely disabling; effective treatment is (as well as a limited number of non- Experimental Medicine, College not only essential for patients but is rewarding pharmaceutical strategies). of Medical and Dental Sciences, for the physician. In this first of two parts review The University of Birmingham, of headache, we provide an overview of Birmingham, UK THE COMMON PRIMARY HEADACHE 2Neurology Department, headache management, emerging therapeutic DISORDERS University Hospitals Birmingham strategies and an accessible interpretation of In European populations, the annual sex- NHS Trust, Queen Elizabeth clinical guidelines to assist the busy neurologist. Hospital Birmingham, adjusted prevalence for tension-type Birmingham, UK headache is 35%, for migraine is 38%, 3 Department of Neurology, Royal BACKGROUND but for cluster headache is only Stoke University Hospital, ’ 0.15%.45These three together comprise Stoke-on-Trent, UK Headache is listed among the WHO s 4Headache Group, Institute of major causes of disability with a global the most prevalent primary headache dis- Neurology, London, UK prevalence of 47% (symptoms occurring orders.
    [Show full text]
  • Thermodynamic Investigation of Promethazine, Loratadine, Cetirizine and Buclizine As Antihistamine Drugs; Monte Carlo and Semi-Empirical Studies
    ISSN-E 1995-9516 Universidad Nacional de Ingeniería COPYRIGHT © (UNI). TODOS LOS DERECHOS RESERVADOS http://revistas.uni.edu.ni/index.php/Nexo https://doi.org/10.5377/nexo.v33i01.10050 Vol. 33, No. 01, pp. 94-108/Junio 2020 THERMODYNAMIC INVESTIGATION OF PROMETHAZINE, LORATADINE, CETIRIZINE AND BUCLIZINE AS ANTIHISTAMINE DRUGS; MONTE CARLO AND SEMI-EMPIRICAL STUDIES INVESTIGACIÓN TERMODINÁMICA DE PROMETAZINA, LORATADINA, CETIRIZINA Y BUCLIZINA COMO MEDICAMENTOS ANTIHISTAMÍNICOS; MONTE CARLO Y ESTUDIOS SEMI-EMPÍRICOS Mina Zakeri1, Majid Monajjemi2*, Ali Ebrahimi3 1Department of Chemistry, Science and Research Branch, Islamic Azad University, Tehran, Iran 2Department of Chemical Engineering, Central Tehran branch, Islamic Azad University Tehran, Iran 3Department of chemistry, Computational Quantum Chemistry Laboratory, University of Sistan and Baluchestan, Iran *[email protected] (recibido/received: 14-diciembre-2019; aceptado/accepted: 21-febrero-2020) ABSTRACT In this article, we discussed about four antihistamine drug called promethazine, loratadine, cetirizine and buclizine. Promethazine in this list is the only one in first generation antihistamine classification with CNS sedation effect and the other three belongs to second generation antihistamine group which are non- sedation and used to treat in many different anti-allergenic fields. In the following we optimized potential, kinetic and total energy of these molecules at body temperature (310 k˚) and environment temperature (298 k ˚) using Mont Carlo method in Amber force field in 500 ns. The quantum mechanics calculations and molecular structure of these molecules investigated using B3LYP level of theory with 6-31 G (d) as a basis set. Theoretical computations were performed to study thermodynamic parameters and frequency analysis. Electronic, thermal, zero point and gibs free energy and enthalpy were estimated in frequency analysis.
    [Show full text]
  • LEGISLATIVE ASSEMBLY Question on Notice
    LEGISLATIVE ASSEMBLY Question On Notice Thursday, 15 February 2018 2560. Ms M. M Quirk to the Minister for Police; I refer to the commencement of operation of the Road Traffic Amendment Act 2016 in March 2017 which introduced compulsory blood or urine samples to be taken from drivers involved in serious crashes, and I ask: (a) since March 2017 how many such samples have been taken; (b) for what specific substances are those blood or urine samples tested; (c) what are the results of those tests to date; and (d) what percentage of drivers have been found to have ingested more than one substance capable of impairing driving skills? Answer (a) The compulsory taking of blood from all drivers involved in serious crashes commenced on 10 March 2017. Between 10 March 2017 and 22 February 2018 (inclusive) a total of 398 blood test samples have been collected under the provision of the Road Traffic Amendment Act 2016. There have been no urine tests collected. (b) Please see attached table for a list of substances in blood sample that are identifiable in ChemCentre toxicology analysis (Paper Number). (c) Of the 398 blood samples collected, 48 are pending results of ChemCentre analysis. Of the 350 analysed, 259 samples had a specific substance(s) detected and 91 samples had no specific substance detected. d) Of the 259 samples with specific substance(s) detected, 92% were found to have multiple substances (more than one). Detectable Substances in Blood Samples capable of identification by the ChemCentre WA. ACETALDEHYDE AMITRIPTYLINE/NORTRIPTYLINE
    [Show full text]
  • Continuous-Flow Multistep Synthesis of Cinnarizine, Cyclizine, and a Buclizine Derivative from Bulk Alcohols
    Continuous-flow multistep synthesis of cinnarizine, cyclizine, and a buclizine derivative from bulk alcohols Citation for published version (APA): Borukhova, S., Noël, T., & Hessel, V. (2015). Continuous-flow multistep synthesis of cinnarizine, cyclizine, and a buclizine derivative from bulk alcohols. ChemSusChem, 9(1), 67-74. https://doi.org/10.1002/cssc.201501367 DOI: 10.1002/cssc.201501367 Document status and date: Published: 09/12/2015 Document Version: Publisher’s PDF, also known as Version of Record (includes final page, issue and volume numbers) Please check the document version of this publication: • A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Cumulative Use of Strong Anticholinergics and Incident Dementia: a Prospective Cohort Study
    Supplementary Online Content Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. Published online January 26, 2015. doi:10.1001/jamainternmed.2014.7663. eTable 1. List of Anticholinergics and Minimum Effective Daily Dose eTable 2. Risk for Incident Dementia and Alzheimer Disease With 10-Year Cumulative Anticholinergic Use According to Subtype eTable 3. Risk for Incident Dementia and Alzheimer Disease With 10-Year Cumulative Anticholinergic Use Adjusted for Recent Depressive Symptoms eTable 4. Risk for Incident Dementia and Alzheimer Disease With 9-Year Cumulative Anticholinergic Use With 2-Year Lag Time eTable 5. Risk for Incident Dementia and Alzheimer Disease Dividing Heavy Anticholinergic Use Into Past, Recent, and Continuous eFigure 1. Example Calculation of Total Standardized Daily Dose eFigure 2. Scheme for Exposure Definition for Primary and Exploratory Analysis This supplementary material has been provided by the authors to give readers additional information about their work. © 2015 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/30/2021 eTable 1. List of anticholinergics and minimum effective daily dosea Antihistamines Antiparkinson agents Gastrointestinal antispasmodics b Azatadine (2 mg) Benztropine (0.5 mg) Adiphenine Bromodiphenhydramine Biperiden Alverine Brompheniramine (12 mg) Chlorphenoxamine Anisotropine Carbinoxamine Cycrimine Atropine products (0.0582 Chlorpheniramine
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Myelogram-Medications-To-Avoid.Pdf
    Medication to be held 48 Banaflex /skeletal muscle relaxer Clozaril/antischizophenia HOURS BEFORE AND 24 HOURS Bancap/contains caffei Cogentin/antidyskinectic/ant AFTER MYELOGRAM Banzel/seizure adjunct iemetic/antipsychotic Updated December 2016 BC powder/ contains caffeine Compazine/phenothiazine Belviq/appetite suppressant Concerta/CNS stimulant Abilify / antipsychotic Bevespi contains formoterol Contrave/antidepressant Acetophenazine/ antipsychotic Benzphetamine/appetite Cyclizine/ antiemetic Adderall/amphetamine and suppressant antivertigo agent dextroamphetamine Bismuth subcitrate potassium/ Cyclobenzaprine/muscle Adipex-P/stimulant/ anorectic mineral relaxer Adsuva/antidepressant Bonine/meclicine Cylert/ADHD agent Adphen/ /antidepressant Bontril/appetite suppressant Cymbalta/antidepressant/tri appetite suppressant Bontril PDM/appetite suppressant cyclic Adipost/ appetite suppressants, Bortezomib/antineoplastics Sympathomimetic (Systemic Brintxelli / antidepressant Adrafinil/cognitive enhancer Bucladin-S softab/antiemetic Dapex/appetite suppressant Alatrofloxacin/ antibacterial antivertigo Dayquil/contains caffeine Aliskiren Bucet/contains caffeine Darvon 65/contain caffeine Hemifumarate/antihypertensive Buclizine/antiemetic/antivertigo Daytrana/CNS stimulant direct renal inhibitor / Budeption/antidepressant Desipramine/tricyclic/antide Alsuma/s Buphenamine/appetite suppressant pressant Amaphen/ barbituate Buproban/antidepressantr Desoxyn/amphetamine Amitriptyline/ tricyclic BupropionBuffets/caffeine Desvenlafaxine succinate/ antidepressant
    [Show full text]